Drug Trial Radar · NCT04961996
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
4,170
Actual
Start
Aug 27, 2021
Primary completion
Aug 8, 2025
Study completion Sep 30, 2033
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jul 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of endocrine therapy in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
Conditions
- Early Breast Cancer
Interventions
GiredestrantDrug
Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).
Physician's Choice of Endocrine TherapyDrug
The physician's choice of endocrine therapy (PCET) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane. Participants will receive PCET daily on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first). Continuing PCET after 5 years is at the discretion of the investigator and per local standard of care. Dose administration of PCET should be performed in accordance with the local prescribing information for the respective product.
LHRH AgonistDrug
A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. LHRH agonists may include, but are not limited to, leuprolide acetate, goserelin acetate, or triptorelin pamoate. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease-Free Survival (IDFS), Excluding Second Primary Non-Breast CancersTime frame: From randomization to first occurrence of an IDFS event (up to 10 years)
Locations
621 sites in 54 countries. Site status is shown where the registry gives one.
Southern Cancer Center
Daphne, Alabama
CBCC Global Research Inc., at Comprehensive Blood and Cancer Center
Bakersfield, California
St Joseph Heritage Healthcare
Fullerton, California
Long Beach Memorial Medical Center
Long Beach, California
Cancer and Blood Specialty Clinic-California-Katella Ave
Los Alamitos, California
The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange
Orange, California
Kaiser Permanente - San Diego
San Diego, California
Sansum Clinic
Santa Barbara, California
UCLA Hematology/Oncology
Santa Monica, California
Torrance Memorial Physician Network/Cancer Care
Torrance, California
Kaiser Permanente - Vallejo
Vallejo, California
Rocky Mountain Cancer Centers (Longmont) - USOR
Longmont, Colorado
Stamford Hospital
Stamford, Connecticut
Memorial Healthcare System - Memorial Regional Hospital
Hollywood, Florida
Baptist - MD Anderson Cancer Center
Jacksonville, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
University of Chicago Hospital
Chicago, Illinois
Duly Health and Care
Tinley Park, Illinois
Cancer Center of Kansas - Kingman
Kingman, Kansas
University of Kentucky
Lexington, Kentucky
Norton Cancer Institute - MDC
Louisville, Kentucky
Hematology/Oncology Clinic, LLP
Baton Rouge, Louisiana
University Medical Center New Orleans
New Orleans, Louisiana
University of Maryland
Towson, Maryland
Lahey Clinic Med Ctr
Burlington, Massachusetts
Massachusetts General Hospital
Lexington, Massachusetts
University Of Michigan
Ann Arbor, Michigan
Metro-Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota
University of Missouri-Columbia
Columbia, Missouri
St. Vincent Frontier Cancer Center
Billings, Montana
Nebraska Cancer Specialists
Omaha, Nebraska
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Hunterdon Hematology Oncology
Flemington, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
New York University Cancer Cen
New York, New York
Stony Brook Univ Cancer Ctr
Stony Brook, New York
Messino Cancer Centers
Asheville, North Carolina
Rex Cancer Center
Raleigh, North Carolina
Atrium Health Wake Forest Baptist Medical Center - PPDS
Winston-Salem, North Carolina
Aultman Hospital
Canton, Ohio
Showing 40 of 621 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.